Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody designed to target LIGHT, a cytokine related to tumor necrosis factor (TNF) identified as TNFSF14. This cytokine is critically involved in the pathogenesis of acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS), particularly noted in COVID-19 cases. The therapeutic potential of Quisovalimab extends to its application in research focused on COVID-19-induced ARDS and related inflammatory conditions, providing a valuable tool for studies aimed at understanding and mitigating cytokine-mediated diseases.
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody designed to target LIGHT, a cytokine related to tumor necrosis factor (TNF) identified as TNFSF14. This cytokine is critically involved in the pathogenesis of acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS), particularly noted in COVID-19 cases. The therapeutic potential of Quisovalimab extends to its application in research focused on COVID-19-induced ARDS and related inflammatory conditions, providing a valuable tool for studies aimed at understanding and mitigating cytokine-mediated diseases.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
